59862-83-8

Upstream product

• 26726-16-9 5-bromofuran-2-carbonyl chloride 
• 865-48-5 sodium t-butanolate 
• 32460-00-7 2,5-dibromofuran 
• 24424-99-5 di-tert-butyl dicarbonate 
• 88-14-2 2-furanoic acid 
• 585-70-6 5-bromo-furan-2-carboxylic acid 
• 36805-97-7 N,N-dimethylformamide di-tert-butyl acetal 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 937377-68-9 4-[5-(tert-butoxycarbonyl)-2-furyl]benzoic acid 
• 937377-71-4 tert-butyl 5-{4-[(benzylamino)carbonyl]phenyl}-2-furoate 
• 937377-72-5 tert-butyl 5-{4-[(biphenyl-4-ylmethylamino)carbonyl]phenyl}-2-furoate 
• 937377-69-0 C₁₆H₁₅O₄Cl 
• 937377-70-3 tert-butyl 5-(4-{[(4-benzoylphenyl)amino]carbonyl}phenyl)-2-furoate 
• 945468-34-8 tert-butyl 5-(3-cyano-4-fluorophenyl)-furan-2-carboxylate 
• 1311149-70-8 2-[2-(trimethylsilyl)ethynyl]-N-{2-[5-(tert-butoxycarbonyl)furan-2-yl]ethynyl}-N-tosylbenzenamine 
• 1311149-81-1 2-({2-[5-(tert-butoxycarbonyl)furan-2-yl]}ethynyl)-N-[2-(trimethylsilyl)ethynyl]-N-tosyl-benzenamine 
• 29700-20-7 perlolyrine 
• 1311149-42-4 methyl 1-[5-(tert-butoxycarbonyl)furan-2-yl]-9-tosyl-9H-pyrido[3,4-b]indole-3-carboxylate 
• 1311149-87-7 methyl 4-[5-(tert-butoxycarbonyl)furan-2-yl]-9-tosyl-9H-pyrido[3,4-b]indole-3-carboxylate 
• 1311149-92-4 methyl 1-(5-(tert-butoxycarbonyl)furan-2-yl)-5-tosyl-5H-pyrido[4,3-b]indole-3-carboxylate 
• 1311149-56-0 1-[5-(tert-butoxycarbonyl)furan-2-yl]-9-tosyl-9H-pyrido[3,4-b]indole-3-carboxylic acid 
• 1311149-60-6 1-[5-(tert-butoxycarbonyl)furan-2-yl]-9-tosyl-9H-pyrido[3,4-b]indole-3-carboxylic acid 

Relevant academic research and scientific papers

In Vivo Half-Life Extension of BMP1/TLL Metalloproteinase Inhibitors Using Small-Molecule Human Serum Albumin Binders

Reducing the required frequence of drug dosing can improve the adherence of patients to chronic treatments. Hence, drugs with longer in vivo half-lives are highly desirable. One of the most promising approaches to extend the in vivo half-life of drugs is conjugation to human serum albumin (HSA). In this work, we describe the use of AlbuBinder 1, a small-molecule noncovalent HSA binder, to extend the in vivo half-life and pharmacology of small-molecule BMP1/TLL inhibitors in humanized mice (HSA KI/KI). A series of conjugates of AlbuBinder 1 with BMP1/TLL inhibitors were prepared. In particular, conjugate c showed good solubility and a half-life extension of >20-fold versus the parent molecule in the HSA KI/KI mice, reaching half-lives of >48 h with maintained maximal inhibition of plasma BMP1/TLL. The same conjugate showed a half-life of only 3 h in the wild-type mice, suggesting that the half-life extension was principally due to specific interactions with HSA. It is envisioned that conjugation to AlbuBinder 1 should be applicable to a wide range of small molecule or peptide drugs with short half-lives. In this context, AlbuBinders represent a viable alternative to existing half-life extension technologies.

Synthesis of [2,2’]Bifuranyl-5,5’-dicarboxylic Acid Esters via Reductive Homocoupling of 5-Bromofuran-2-carboxylates Using Alcohols as Reductants?

Herein, we describe an environmentally benign and cost-effective protocol for the synthesis of valuable bifuranyl dicarboxylates, starting with α-bromination of readily accessible furan-2-carboxylates by LiBr and K2S2O8. Furthermore, the bromination intermediate product 5-bromofuran-2-carboxylates were then conducted in a palladium-catalyzed reductive homocoupling reactions in the presence of alcohols to afford bifuranyl dicarboxylates. One of the final products in this protocol, [2,2’]bifuran-5,5’-dicarboxylic acid esters, are essential monomers of poly(ethylene bifuranoate), which can be served as an green and versatile alternative polymer for traditional poly(ethylene terephthalate) that is currently common in technical plastics.

Method for preparing 2,5-furandicarboxylic acid

The invention discloses a method for preparing 2,5-furandicarboxylic acid. The method comprises the following steps: preparing the 2,5-furandicarboxylic acid by sequentially performing four-step reaction namely bromination reaction, esterification reaction, carbonylation reaction and hydrolysis reaction on furan-2-carboxylic acid, wherein a compound as shown in Formula 3, a compound as shown in Formula 4 and a compound as shown in Formula 5 are obtained by the bromination reaction, the esterification reaction and the carbonylation reaction respectively. Compared with the prior art, the invention can effectively solve the problem of not high yield or severe reaction condition requirement by improving the key overall process flow of the preparation method and reaction conditions of each step. The structural formulae of the compound as shown in Formula 3, the compound as shown in Formula 4 and the compound as shown in Formula 5 are as shown in the specification respectively.

[2+2+2] Cycloadditions of alkynylynamides - A total synthesis of perlolyrine and the first total synthesis of "isoperlolyrine"

The total syntheses of the carboline alkaloids perlolyrine and "isoperlolyrine" are reported. Key-steps of the syntheses are Negishi coupling reactions on alkynylynamides and their metal-catalyzed [2+2+2] cycloadditions with nitriles to form the β- and γ-

Highly selective and efficient conversion of aryl bromides to t-butyl benzoates with di-t-butyl dicarbonate

t-Butyl benzoates can be accessed from aromatic compounds bearing multiple halogen substituents via selective metal-halogen exchange with lithium tri-n-butylmagnesium ate complex followed by trapping with di-t-butyl dicarbonate.

NMR screening applied to the fragment-based generation of inhibitors of creatine kinase exploiting a new interaction proximate to the ATP binding site

Using an in-house fragment NMR library, we identified a set of ligands that bind rabbit muscular creatine kinase, an enzyme involved in key ATP-dependent processes. The ligands docked to the crystal structures of creatine kinase indicated that a phenylfur